Dyadic International, Inc. (DYAI)

Market Cap	37.01M
Revenue (ttm)	3.50M
Net Income (ttm)	-5.81M
Shares Out	30.09M
EPS (ttm)	-0.20
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	13,724
Open	1.225
Previous Close	1.240
Day's Range	1.210 - 1.240
52-Week Range	0.930 - 2.670
Beta	0.98
Analysts	Strong Buy
Price Target	6.00 (+391.8%)
Earnings Date	May 13, 2025

About DYAI

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells industrial enzymes and other proteins in the United States and internationally. It utilizes the C1 platform in pharmaceutical applications, including the development and production of pharmaceutical products. The company offers Dapibus, a protein production platform that enable the rapid development and large-scale manufacture of cost-effective enzymes, proteins, metabolites, and other biologic products for life sciences, food and nutrition, and bioindus...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 5, 2004
• Employees: 6
• Stock Exchange: NASDAQ
• Ticker Symbol: DYAI
• Website: https://www.dyadic.com

Financial Performance

In 2024, Dyadic International's revenue was $3.50 million, an increase of 20.58% compared to the previous year's $2.90 million. Losses were -$5.81 million, -14.51% less than in 2023.

Analyst Forecast

According to one analyst, the rating for DYAI stock is "Strong Buy" and the 12-month stock price forecast is $6.0.

Price Target

$6.0

(391.80% upside)

Analyst Consensus: Strong Buy